These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 27865689)
1. Retinal oximetry during treatment of retinal vein occlusion by ranibizumab in patients with high blood pressure and dyslipidemia. Keilani C; Halalchi A; Wakpi Djeugue D; Regis A; Abada S J Fr Ophtalmol; 2016 Dec; 39(10):816-821. PubMed ID: 27865689 [TBL] [Abstract][Full Text] [Related]
2. Retinal Oxygen Saturation Correlates With Visual Acuity but Does Not Predict Outcome After Anti-VEGF Treatment in Central Retinal Vein Occlusion. Jeppesen SK; Bek T Invest Ophthalmol Vis Sci; 2017 May; 58(5):2498-2502. PubMed ID: 28470332 [TBL] [Abstract][Full Text] [Related]
3. Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population. Gu X; Yu X; Song S; Dai H Ophthalmic Res; 2017; 58(1):8-14. PubMed ID: 28334720 [TBL] [Abstract][Full Text] [Related]
4. Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study. Wroblewski JJ; Hu AY Ophthalmic Surg Lasers Imaging Retina; 2016 Oct; 47(10):914-923. PubMed ID: 27759857 [TBL] [Abstract][Full Text] [Related]
5. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066 [TBL] [Abstract][Full Text] [Related]
6. Retinal oximetry does not predict 12-month visual outcome after anti-VEGF treatment for central retinal vein occlusion: A multicentre study. Krejberg Jeppesen S; Sín M; Hakon Hardarson S; Bek T Acta Ophthalmol; 2021 Nov; 99(7):e1141-e1145. PubMed ID: 33421320 [TBL] [Abstract][Full Text] [Related]
7. The Role of Serum Inflammation-Based Factors in Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Retinal Vein Occlusion and Its Subtypes. Rao J; Wu N; Qu X; Hu Y; Wu Y; Cheng Y; Yan L; Huang H; Li S; Shi L; Wu X Ophthalmic Res; 2021; 64(2):237-245. PubMed ID: 32506058 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of best corrected visual acuity and central macular thickness after intravitreal dexamethasone implant injections in patients with Irvine-Gass syndrome: A retrospective study of six cases. Keilani C; Halalchi A; Wakpi Djeugue D; Regis A; Abada S Therapie; 2016 Oct; 71(5):457-465. PubMed ID: 27203164 [TBL] [Abstract][Full Text] [Related]
9. Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion. Kaya F; Kocak I; Aydin A; Baybora H; Koc H; Karabela Y J Fr Ophtalmol; 2018 Nov; 41(9):809-813. PubMed ID: 30361176 [TBL] [Abstract][Full Text] [Related]
10. Retinal vascular oximetry during ranibizumab treatment of central retinal vein occlusion. Traustason S; la Cour M; Larsen M Br J Ophthalmol; 2014 Sep; 98(9):1208-11. PubMed ID: 24729079 [TBL] [Abstract][Full Text] [Related]
11. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977 [TBL] [Abstract][Full Text] [Related]
12. Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab. Brogan K; Precup M; Rodger A; Young D; Gilmour DF BMC Ophthalmol; 2018 Feb; 18(1):37. PubMed ID: 29426292 [TBL] [Abstract][Full Text] [Related]
13. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes. Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625 [TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion. Kim M; Yu SY; Kim ES; Bae SH; Park JH; Yu HG; Kwak HW Ophthalmologica; 2012; 227(3):132-8. PubMed ID: 22212151 [TBL] [Abstract][Full Text] [Related]
15. [Morphologic Patterns on Spectral-Domain Optical Coherence Tomography (SD-OCT) as a Prognostic Indicator in Treatment of Macular Edema Due to Retinal Vein Occlusion]. Groneberg T; Trattnig JS; Feucht N; Lohmann CP; Maier M Klin Monbl Augenheilkd; 2016 Sep; 233(9):1056-62. PubMed ID: 26854482 [TBL] [Abstract][Full Text] [Related]
17. Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab. Narayanan R; Kelkar A; Abbas Z; Goel N; Soman M; Naik N; Sudhalkar A; Walinjkar J; Shah U; Maksane N BMC Ophthalmol; 2021 Jan; 21(1):33. PubMed ID: 33435908 [TBL] [Abstract][Full Text] [Related]
18. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study. Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142 [TBL] [Abstract][Full Text] [Related]
19. Comparison of anti-VEGF results between non-ischemic branch retinal vein occlusion and ischemic branch retinal vein occlusion with early sector panretinal photocoagulation. Akdemir SC; Gunay BO J Fr Ophtalmol; 2022 Nov; 45(9):1042-1047. PubMed ID: 36127168 [TBL] [Abstract][Full Text] [Related]
20. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months. Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ Retina; 2010; 30(7):1002-11. PubMed ID: 20616679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]